PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20543519-11	2010	Both TG content and ApoB-48 mass were decreased in ezetimibe-treated mice.	Ezetimibe	51-60	apolipoprotein B	Mus musculus	20-27	
20543519-12	2010	The quantitative RT-PCR of intestinal mucosa showed down-regulation of the mRNA expression of FATP4 and ApoB in both groups along with FABP2, DGAT1, DGAT2 and SCD1 in WT mice at postprandial state after ezetimibe treatment.	Ezetimibe	203-212	apolipoprotein B	Mus musculus	104-108	
20543519-13	2010	CONCLUSION: Ezetimibe alone reduces PHTG by blocking both the absorption of cholesterol and the intracellular trafficking and metabolism of long-chain fatty acids in enterocytes, resulting in the reduction of the formation of ApoB-48 which is necessary for the ApoB48-containing lipoprotein production in the small intestines.	Ezetimibe	12-21	apolipoprotein B	Mus musculus	226-233	
20543519-13	2010	CONCLUSION: Ezetimibe alone reduces PHTG by blocking both the absorption of cholesterol and the intracellular trafficking and metabolism of long-chain fatty acids in enterocytes, resulting in the reduction of the formation of ApoB-48 which is necessary for the ApoB48-containing lipoprotein production in the small intestines.	Ezetimibe	12-21	apolipoprotein B	Mus musculus	261-267	
18585981-6	2008	In Npc1l1/apoE null mice or apoE null mice treated with ezetimibe plasma cholesterol levels were reduced primarily in the apoB48 containing chylomicron remnant lipoproteins relative to untreated apoE null mice.	Ezetimibe	56-65	apolipoprotein B	Mus musculus	122-128